Fernand Labrie
Publications
Page 1 of 2, showing 50 records out of 64 total, starting on record 1, ending on 50
| Publication | Category | Year |
|---|---|---|
| 64. Donet, E., Bayo, P., Calvo, E., Labrie, F., Pérez, P. (2008) Identification of novel glucocorticoid receptor-regulated genes involved in epidermal homeostasis and hair follicle differentiation. J Steroid Biochem Mol Biol, 108: 8-16. | Acolbifene | 2008 |
| 63. Labrie, F. (2008) Combination of Breast Cancer Prevention with Tissue-Targeted Hormone Replacement Therapy, In: Breast Cancer - Prognosis, Treatment, and Prevention, Second Edition, Pasqualini, J.R., ed., pp. 201-252. | Acolbifene | 2008 |
| 62. Labrie, F. (2007) Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab, 3: 584-93. | Acolbifene | 2007 |
| 61. Sancéau, J.-Y., Larouche, D., Caron, B., Bélanger, P., Coquet, A., Bélanger, A., Labrie, F., Gauthier, S. (2007) Synthesis and deuterium labelling of the pure selective estrogen receptor modulator (SERM) acolbifene glucuronides. J. of Label Compd and Radiopharm, 50: 197-206. | Acolbifene | 2007 |
| 60. Labrie, F. (2006) Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer, 13: 335-355. | Acolbifene | 2006 |
| 59. Liby, K., Rendi, M., Suh, N., Royce, D.B., Risingsong, R., Williams, C.R., Lamph, W., Labrie, F., Krajewsi, S., Xu, X., Kim, H., Brown, P., Sporn, M.B. (2006) The Combination of the Rexinoid, LG100268, and a SERM, either Arzoxifene or Acolbifene, Synergize in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor Negative Model of Breast Cancer. Clin Cancer Res, 12: 5902-5909. | Acolbifene | 2006 |
| 58. Lemieux, C., Gélinas, Y., Lalonde, J., Labrie, F., Richard, D., Deshaies, Y. (2006) Hypocholesterolemic action of the selective estrogen receptor modulator acolbifene in intact and ovariectomized rats with diet-induced hypercholesterolemia. Metabolism, 55: 605-13. | Acolbifene | 2006 |
| 57. Gauthier, S., Cloutier, J., Dory, Y.L., Favre, A., Mailhot, J., Ouellet, C., Schwerdteeger, A., Mérand, Y., Martel, C., Simard, J., Labrie, F. (2005) Synthesis and structure-activity relationships of analogs of EM-652 (acobifene), a pure selective estrogen receptor modulator. Study of mitrogen substitution. J of Enzyme Inhibition and Medicinal Chemistry, 20: 165-177. | Acolbifene | 2005 |
| 56. Lemieux, C., Gélinas, Y., Lalonde, J., Labrie, F., Cianflone, K., Deshaies, Y. (2005) Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-B1 and LDL receptors. J. of Lipid Research, 46: 1285-94. | Acolbifene | 2005 |
| 55. Lemieux, C., Gélinas, Y., Lalonde, J., Labrie, F., Richard, D., Deshaies, Y. (2005) The selective estrogen receptor modulator acolbifene reduces cholesterolemia idependently of its anorectic action in control and cholesterol-fed rats. J Nutr, 135: 2225-9. | Acolbifene | 2005 |
| 54. Lemieux, C., Phaneuf, D., Labrie, F., Giguère, V., Richard, D., Deshaies, Y. (2005) Estrogen receptor alpha-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene. Int J Obes, 29: 1236-44. | Acolbifene | 2005 |
| 53. Labrie, F., Champagne, P., Labrie, C., Roy, J., Laverdiere, J., Provencher, L., Potvin, M., Drolet, Y., Pollak, M., Panasci, L., L'Espérance, B., Dufresne, J., Latreille, J., Robert, E., Samson, B., Jolivet, J., Yelle, L., Cusan, L., Diamond, P., Candas, B. (2004) Activity and safety of the orally active precursor of EM-652 (Acolbifene) in Tamoxifen-resistant breast cancer. J Clin Oncol, 22: 864-871. | Acolbifene | 2004 |
| 52. Sancéau, J.-Y., Labrie, F., Gauthier, S. (2004) Synthesis of 14C-labelled EM-800 (SCH 57050) and EM-652. HCI (SCH 57068. HCI, acolbifene), pure selective estrogen receptor modulators. J. of Label Compounds & Radiopharmaceuticals, 47: 741-752. | Acolbifene | 2004 |
| 51. Gutman, M., Couillard, C., Labrie, F., Candas, B., Labrie, C. (2003) Effect of treatment sequence with radiotherapy and the antiestrogen EM-800 on the growth of ZR-75-1 Human mammary carcinoma in nude mice. Int J Cancer, 103: 268-276. | Acolbifene | 2003 |
| 50. Jensen, J., Kitlen, J., Briand, P., Labrie, F., Lykkesfeldt, A.E. (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J. Steroid Biochem Mol Biol, 84: 469-78. | Acolbifene | 2003 |
| 49. Labrie, F., El Alfy, M., Berger, L., Labrie, C., Martel, C., Bélanger, A., Candas, B., Pelletier, G. (2003) The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology, 144: 4700-4706. | Acolbifene | 2003 |
| 48. Roy, J., Couillard, C., Gutman, M., Labrie, F. (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat, 81: 223-229. | Acolbifene | 2003 |
| 47. Lemieux, C., Picard, F., Labrie, F., Richard, D., Deshaies, Y. (2003) The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity. Obes. Res., 11: 477-490. | Acolbifene | 2003 |
| 46. Barbier, O., Albert, C., Martineau, I., Vallée, M., High, K., Labrie, F., Hum, D.W., Labrie, C., Bélanger, A. (2003) Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068) by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymes. Mol Pharmacol, 59: 636-45. | Acolbifene | 2003 |
| 45. Labrie, F. (2003) Extragonadal synthesis of sex steroïds: Intracrinology. Ann. Endocrinol, 64: 95-107. | Acolbifene | 2003 |
| 44. Tatchum-Talom, R., Martel, C., Labrie, F., Marette, A. (2003) Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. J. of the European Soc. of Cardiology, 57: 535-543. | Acolbifene | 2003 |
| 43. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. | Acolbifene | 2002 |
| 42. Gutman, M., Couillard, S., Roy, J., Labrie, F., Candas, B., Labrie, C. (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 99: 273-278. | Acolbifene | 2002 |
| 41. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. | Acolbifene | 2002 |
| 40. Labrie, F., Labrie, C., Bélanger, A., Simard, J. (2002) Third and fourth generation SERMs, in: Manni, A. et Verderame, M., eds: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Totowa, NJ, Humana Press Inc., pp 167-187. | Acolbifene | 2002 |
| 39. Bernardi, F., Stomati, M., Luisi, S., Pieri, M., Labrie, F., Geneazzani, A.R. (2002) Effects of the new generation selective estrogen receptor modulator EM-652 and oral administration of estradiol valerate on circulating, brain, and adrenal ?-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats. Fertility and Sterility, 77: 1018-1027. | Acolbifene | 2002 |
| 38. Simoncini, T., Varone, G., Fornari, L., Mannella, P., Labrie, F., Genazzani, A.R. (2002) Genomic and non-genomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth generation selective estrogen receptor modulator. J. Endocrinol, 143: 2052-2061. | Acolbifene | 2002 |
| 37. Barbier, O., Albert, C., Martineau, I., Vallée, M., High, K., Labrie, F., Hum, D.W., Labrie, C., Bélanger, A. (2001) Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068), by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymes. Mol Pharmacol., 59: 636-45. | Acolbifene | 2001 |
| 36. Labrie, F., Labrie, C., Bélanger, A., Giguère, V., Simard, J., Mérand, Y., Gauthier, S., Luu-The, V., Candas, B., Martel, C.E.A. (2001) Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, in: Scolnick, E.M., ed. Advances in Protein Chemistry, San Diego, CA, Academic Press, pp 293-368. | Acolbifene | 2001 |
| 35. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Giguère, V., Tremblay, A., Tremblay, G. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 79: 213-225. | Acolbifene | 2001 |
| 34. Labrie, F., Simard, A.R., Labrie, C., Bélanger, A. (2001) EM-652 (SCH57068) a pure SERM in the mammary gland and endometrium. Référence en Gynécologie Obstétrique, 8: 331-336. | Acolbifene | 2001 |
| 33. Pelletier, G., El Alfy, M., Labrie, C., Martel, C., Labrie, F. (2001) Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor ? and prolactin mRNA expression in intact, ovariectomized and GnRH-treated female rats. Neuroendocrinology, 74: 367-374. | Acolbifene | 2001 |
| 32. Sauvé, F., McBroom, L.D.B., Gallant, J., Moraitis, A.N., Labrie, F., Giguère, V. (2001) CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol. Cell. Biol, 21: 343-353. | Acolbifene | 2001 |
| 31. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. | Acolbifene | 2000 |
| 30. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., Singh, S.M., Candas, B., Labrie, F. (2000) Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int. J. Cancer, 85: 424-429. | Acolbifene | 2000 |
| 29. Labrie, C., Labrie, F., Bélanger, A., Simard, J., Luo, S., Martel, C. (2000) EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, in: Coutinho, E.M. et Spinola, P., eds: Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May 1999, Elsevier Science B.V., pp 381-397. | Acolbifene | 2000 |
| 28. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Luu-The, V., Candas, B. (2000) Mechanisms of action of estrogens and antiestrogens, in: Aso, T., Yanaihara, T. et Fujimoto, S., eds: The Menopause at the Millenium: Proceedings of the 9th World Congress on the Menopause, October 17-21, 1999, Yokohama, Japan, Parthenon Publishing, pp 14-22. | Acolbifene | 2000 |
| 27. Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., Labrie, F. (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J. Steroid Biochem. Mol. Biol., 74: 45-56. | Acolbifene | 2000 |
| 26. Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Labrie, C., Bélanger, A., Labrie, F., Richard, D. (2000) Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int. J. Obes. Relat. Metab. Disord., 24: 830-840. | Acolbifene | 2000 |
| 25. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. | Acolbifene | 1999 |
| 24. Couillard, S., Gutman, M., Labrie, F., Candas, B., Labrie, C. (1999) Effect of the combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863. | Acolbifene | 1999 |
| 23. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. | Acolbifene | 1999 |
| 22. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. | Acolbifene | 1999 |
| 21. Labrie, F.; (1999). EM-652: a pure anti-estrogen discovered and developed in Canada. The best hope for breast cancer prevention and treatment. Can. Breast Cancer Network, 4: Vol. 4, p. 7. | Acolbifene | 1999 |
| 20. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1999) Dominant activity of activation function-1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor ?/? heterodimeric complex. Mol. Cell. Biol., 19: 1919-1927. | Acolbifene | 1999 |
| 19. Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and Tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64. | Acolbifene | 1998 |
| 18. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. (1998) Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778. | Acolbifene | 1998 |
| 17. Luo, S., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Prevention of development of dimenthylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH 57050). Breast Cancer Res. Treat., 49: 1-11. | Acolbifene | 1998 |
| 16. Luo, S., Sourla, A., Labrie, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, F. (1998) Effect of 24-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology, 139: 2645-2656. | Acolbifene | 1998 |
| 15. Martel, C., Labrie, C., Bélanger, A., Gauthier, S., Mérand, Y., Li, X., Provencher, L., Candas, B., Labrie, F. (1998) Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology, 139: 2486-2492. | Acolbifene | 1998 |